SYNERGA.fund SA
0.42
PLN
+0.01
(+2.44%)
ISIN
PLMWTNS00010
Return %
Stock
S&P 500
1Y
-44.44
14.20
3Y
-60.56
81.12
5Y
-81.66
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Tomasz Wykurz
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Kraków Poland
- IPO Date
- Jun 10, 2011
- Website
- synerga.fund
- Similar Companies
- Business
- SYNERGA.fund SA is a Poland-based investment and biotechnology commercialization company focused on the development, management, and deployment of innovative healthcare technologies and private equity holdings. The company operates primarily across the biotechnology, life sciences, and alternative investment sectors, directing capital and operational capabilities toward advanced clinical therapies and high-growth enterprise ventures. The company organizes its principal business activities and offerings into three primary segments: Biotechnology and Regenerative Medicine, encompassing the proprietary development, regulatory oversight, and commercialization of autologous bone marrow-derived stem cell therapies under the flagship ONGENO brand, designed for the treatment of neurodegenerative diseases including multiple sclerosis (MS) within authorized medical experiment frameworks; Intellectual Property Management, comprising the protection, licensing, and administration of specialized patent assets, treatment protocols, and commercial rights for cellular medical procedures; and Private Equity and Venture Capital Management, providing direct equity financing, transaction advisory, portfolio monitoring, and capital allocation services for early-stage and turnaround corporate investments. SYNERGA.fund SA targets healthcare patients seeking advanced neurological therapies, institutional medical partners, research organizations, and corporate investment targets across Poland and international markets. The company was founded in 2010, is headquartered in Krakow, Poland, and is listed on the NewConnect market of the Warsaw Stock Exchange under the ticker symbol SNG. In recent operations, SYNERGA.fund SA has executed a focused strategic pivot toward the commercial scaling, international brand expansion, and multi-market clinical rollout of its ONGENO stem cell therapy platform. To streamline its investment balance sheet and fund core medical operations, the company concluded the full divestment of its legacy non-core equity holdings, including the sale of its entire shareholding in gaming company All In! Games SA. These operational developments follow broader corporate restructuring initiatives and governance transitions following its historical transformations from Silva Capital Group SA and MW Tenis SA.